Georgia's Assisted Reproductive Technology Ranking and Real-Level Analysis in Europe

A Real Patient Experience from a Practitioner

In the autumn of 2023, I accompanied a 42-year-old client from Beijing to Tbilisi. She had undergone two egg retrievals and three embryo transfers in China, all of which failed to implant, with an AMH level of only 0.8. Before departure, she repeatedly asked me: "Where does Georgia's IVF technology rank in Europe? Is it better than China?" This question seems simple, but the medical evaluation, country differences, and individual choices involved are far more complex than a single ranking number. Below is my objective analysis based on ten years of experience coordinating overseas assisted reproduction.

Direct Answer: No Official Ranking, But There Are Referable Indicators

There is no unified "ranking list" for assisted reproductive technology in Europe. The European Society of Human Reproduction and Embryology (ESHRE) publishes a pan-European IVF data report every two years, but it does not rank countries. However, based on ESHRE's published cycle data, clinical pregnancy rates, and live birth rates from 2019-2022, as well as the laboratory certification levels (e.g., ISO, CAP) of reproductive centers in various countries, Georgia can be compared within the European framework:

• Georgia's IVF live birth rate per single embryo transfer is approximately 35%~45%, similar to Poland, the Czech Republic, and Hungary;
• Lower than Spain (45%~55%), Denmark (50%~60%), and Sweden (55%~65%);
• Higher than some non-top-tier centers in Russia and Moldova, and comparable to pre-war levels in Ukraine.

It is important to note that these data are significantly influenced by clinic size, patient selection criteria, and age distribution. Some large reproductive centers in Georgia (e.g., Vitalab, NANO IVF) achieve live birth rates of over 50% for younger patients (<35 years), on par with the top tier in Eastern Europe.

Physician's Perspective: Laboratory Level is the Key Variable

I interviewed the embryology directors of two reproductive centers in Georgia, and they agreed: the core metric for ranking assisted reproductive technology in Europe is the "laboratory quality control system," not simply the clinical pregnancy rate. Currently, three embryology laboratories in Georgia are ISO 15189 certified, using incubators, gas sources, and micromanipulation equipment from mainstream European brands (e.g., Cook, Vitrolife). In terms of hardware, there is no generational gap compared to medium-sized clinics in Spain. The main differences lie in:

• Training experience of embryologists—most embryologists in Georgia have trained in Ukraine, Israel, or Turkey, but those at top European centers (e.g., IVI Spain, UZ Brussel Belgium) often have longer independent practice periods;
• Utilization rate of genetic testing (PGT)—PGT-A usage in Georgia is about 30%, compared to over 60% in high-end European clinics, which somewhat impacts choices for older patients;
• Embryo freezing and thawing techniques—Georgia primarily uses vitrification, with a thaw survival rate >95%, consistent with European standards.

The main factors physicians consider when determining suitability for Georgia are female age, ovarian reserve, and reasons for previous failures. For individuals under 35 with normal ovarian function and no complex genetic history, Georgia's laboratory conditions are sufficient to support high success rates.

Country Differences: Georgia's Unique Position

As shown in the table, Georgia does not have an advantage in success rates, but its legal openness to surrogacy and egg donation is higher than in most European countries (surrogacy is illegal in Spain and Belgium). Therefore, for those needing third-party assisted reproduction, Georgia's "technical ranking" must be evaluated in conjunction with legal availability.

Easily Overlooked Details: Selection Bias Behind Ranking Data

Many organizations promote "Georgia's IVF success rate ranks top three in Europe," which is marketing rhetoric. The reality is:

• Some clinics only count patients <38 years old, first cycles, using their own eggs, excluding older and multiple-failure cases, leading to inflated data;
• Top European centers often receive more complex patients (e.g., repeated implantation failure, advanced age, premature ovarian failure), making their live birth rates appear "lower";
• The denominator for "live birth rate" in ESHRE reports varies—calculated per transfer cycle vs. per egg retrieval cycle—with differences of up to 10 percentage points.

The method to assess a clinic's true level is not to look at rankings but to request "live birth rates stratified by age group and number of transfers," as well as the validity period of third-party laboratory certifications.

Common Pitfall: Blindly Chasing Rankings and Ignoring Individual Matching

A client once insisted on going to a "top-ranked in Europe" center in Spain, but ultimately chose Georgia because the center could not provide egg donation materials (requiring a 6+ month wait in Spain) and the budget was exceeded. She overlooked the core issue: technical rankings only reflect averages, while individual success depends on the physician's ability to handle specific cases. In Georgia, common pitfalls include:

• Clinics offering "guaranteed success" packages—rare domestically, but some intermediaries in Georgia promote them, actually increasing costs through multiple retrievals and transfers, and not including embryo genetic testing fees;
• Ignoring language barriers—some doctors have limited English proficiency, and key medical terms (e.g., "endometrial receptivity," "embryo fragmentation rate") need translation, leading to information loss;
• Legal risks related to surrogacy—although Georgia allows surrogacy, procedures for parentage determination and birth certificate processing can vary; in 2023, there was a dispute case involving a surrogate's legal termination of pregnancy.

It is recommended to have a video consultation with the embryologist before choosing, confirming their familiarity with the specific needs of your case (e.g., PGT-SR, endometrial micro-stimulation).

Timeline: From Consultation to Transfer

If choosing Georgia for assisted reproduction, an ideal timeline is as follows:

• Step 1 (1-2 weeks): Collect domestic test reports from the last 6 months (AMH, hormone panel, vaginal ultrasound, semen analysis) and send them to the target clinic for pre-screening;
• Step 2 (1 week): After confirming the clinic, sign legal documents and pay a deposit, while applying for an e-visa to Georgia (most passports allow visa on arrival, but advance application is recommended);
• Step 3 (2-4 weeks): For autologous egg patients, enter Tbilisi on day 2 of menstruation to start ovarian stimulation (about 10-12 days), then stay locally for 3-5 days after egg retrieval;
• Step 4 (1-2 months): If PGT is performed, embryos need biopsy and sent to a third-party genetic testing company (usually in the Czech Republic or Israel), with results taking 4-6 weeks;
• Step 5 (1 week): Transfer cycle (natural or artificial cycle), return home 5-7 days after transfer.

When using egg donation or surrogacy plans, the timeline extends to 6-12 months, depending on donor screening and surrogate matching cycles.

Special Cases: Advanced Age, Low Ovarian Reserve, Repeated Failure

Georgia's technical support for older patients (>40 years) is not weaker than in EU countries. Below is an assessment based on practitioner observations:

• AMH <1.0 ng/mL: Most clinics will recommend direct use of egg donation, as the probability of obtaining a transferable embryo from autologous cycles is <20%. A few centers use mild stimulation or natural cycle protocols, but live birth rates do not exceed 10%.
• Previous 2+ failed transfers: Endometrial receptivity analysis (ERA), chronic endometritis testing (CD138), and immune/coagulation screening are needed. Only 2 laboratories in Georgia can perform ERA, and samples must be sent to Spain. It is recommended to complete such tests domestically before traveling to save time.
• Chromosomal structural abnormalities (e.g., balanced translocation): Georgia can perform PGT-SR, but embryo biopsy requires a 6-8 week wait, and laboratory experience in interpreting complex chromosomes is less than that of large European PGT centers. In such cases, Spain or the US is more suitable.

Special groups (e.g., single parents, LGBT) have higher legal acceptance in Georgia, but should consult local lawyers in advance to confirm how parental information is registered on birth certificates.

Practitioner's Observation: The Real Ecology Behind the Data

Over the past three years, among more than 70 patients I have handled going to Georgia, the autologous egg live birth rate was about 38%, the egg donation live birth rate about 55%, and the surrogacy live birth rate about 45% (referring to successful delivery by the surrogate). These figures are generally consistent with official clinic data, but two key findings emerged:

• Younger patients (<35 years) choosing Georgia have success rates not significantly different from second-tier European countries, but some clinics tend to "over-stimulate"—increasing the starting dose of FSH to boost egg yield, which may lead to OHSS or decreased egg quality. This is related to the clinic's lack of experience in individualized protocol design.
• In the surrogacy process, the physical condition of Georgian surrogates is generally better than in Southeast Asia, but psychological evaluation and ongoing management of surrogates are relatively weak; there was a case where a surrogate took herbal medicine after transfer, leading to miscarriage. It is recommended to choose agencies with a dedicated surrogate management team (including social workers and obstetricians).

Regarding the European ranking, I would summarize it this way: Georgia's assisted reproductive technology is upper-middle in Eastern Europe and mid-to-low in Western Europe, but considering cost-effectiveness and legal inclusivity, for specific populations, Georgia is "the most practical solution to the problem."

Risk Reminder: These Situations Suggest Prioritizing Other Regions

The following groups should not choose Georgia solely for its "European ranking":

• Those needing PGT for maximum embryo screening precision (e.g., HLA matching, single gene disease combined with PGD);
• Age >43 years and insisting on using own eggs (Georgia offers almost no advantage in such cases);
• High demand for medical language communication, unable to accept simple English or Russian;
• Need for comprehensive neonatal intensive care support (NICU)—NICU levels in some Georgian hospitals are limited; high-risk pregnancies should consider Spain or Germany.

Finally, before making any choice, always request the clinic to provide complete cycle data from the last two years (including denominator data) and consult an independent reproductive medicine advisor, rather than relying solely on intermediary ranking tables.